Living with Encapsulating Peritoneal Sclerosis (Eps): The Patient's Perspective

Abstract

♦ Background: Although relatively rare, encapsulating peritoneal sclerosis (EPS) is nonetheless a major concern within the renal community. Risk of developing EPS is associated with long-term peritoneal dialysis (PD). High mortality was previously reported, although surgery has since improved outcomes. Research into EPS focuses on imaging and early detection methods, genetics, biomarkers and preventive strategies. No previous studies have examined patients' experiences of EPS. ♦ Aims: The aim of the present study was to explore the experience of patients who have undergone surgery for EPS in one center in the North of England. ♦ Methods: A qualitative phenomenological approach, involving in-depth interviews, was adopted. Nine participants were recruited out of a total of 18 eligible. Most participants were interviewed twice over a 12-month period (October 2009 to October 2010). ♦ Analysis: Interpretive data analysis was conducted, following the philosophical tradition of hermeneutics, to draw out themes from the data. Data collection and analysis took place concurrently and participants were sent a summary of their first interview to allow a period of reflection prior to the subsequent interview. ♦ Results: EPS presented the most serious challenge participants had faced since developing chronic kidney disease (CKD). Three major themes were identified, each with subcategories. The key issues for patients were related to identification of early symptoms and lack of understanding. The patients' sense of 'not being heard' by health care professionals led to a loss of trust and enhanced their feelings of uncertainty. The enormity of the surgery, the suffering, and what they had to endure had an enormous impact, but an overriding aspect of this experience was also the loss they felt for their independence and for the PD therapy over which they had control. ♦ Conclusions: The findings of this study highlight a number of important issues relevant to clinical practice, including lack of information and understanding of EPS, particularly its early symptoms At the time patients transfer from peritoneal to hemodialysis, the provision of adequate information about the risks and potential early signs of EPS may not only improve their experiences, but may also assist in early detection.Perit Dial Int 2014; 34(7):758-765 www.PDIConnect.com epub ahead of

Very early withdrawal from treatment in patients starting peritoneal dialysis

“…[ 11 ] did not restricted the time of withdrawal. Further, we postulate that over the course of prolonged PD, more patients are likely to transfer to HD due to ultrafiltration failure or to avoid the development of encapsulating peritoneal sclerosis [ 12 , 13 ]. Notably, when restricted to the first 90 days of treatment, similar to our findings, the main reason for PD discontinuation during the first 90 days of treatment in the Kolesynk et al.…”

Length of Time on Peritoneal Dialysis and Encapsulating Peritoneal Sclerosis — Position Paper for ISPD: 2017 Update

“…Of note, the low osmotic (50). Other strategies that have been suggested for EPS prevention include minimization of dialysate glucose administration and prescription of "biocompatible" PD fluids.…”

Significant Decreasing Incidence of Encapsulating Peritoneal Sclerosis in the Dutch Population of Peritoneal Dialysis Patients

“…computed tomography [CT] scan appearance) and functional features (intermittent subacute bowel obstruction). It is important to be clinically aware of the possibility of EPS for many years after stopping PD; failure to listen to the patient and his/her symptoms may lead to a delay in diagnosis (50). Encapsulating peritoneal sclerosis presents after withdrawal from PD in the majority (70 -90% in some series) of patients (11,51) and the time from cessation of PD until the development of EPS has been reported as up to 5 years (52).…”

“…Of note, the low osmotic symptoms were often subtle but not understood. Providing written information is recommended to give the patients control and enable them to discuss their concerns with the healthcare team (50). Other strategies that have been suggested for EPS prevention include minimization of dialysate glucose administration and prescription of "biocompatible" PD fluids.…”